DeLLphi-305 randomized 563 nonprogressing ES-SCLC patients post induction durvalumab plus platinum/etoposide to durvalumab maintenance with or without tarlatamab, with overall survival as the primary ...

Incidental prostate cancer was identified on surgical pathology despite consistently low PSA, highlighting limitations of PSA-based detection in some cases. Peristomal skin integrity depends on ...

Historical shifts in supportive care and cultural expectations helped move cancer guidance from enforced rest toward ...

Metastatic disease can create “long-hauler” survivorship characterized by repeated therapeutic cycles, ongoing vigilance, and psychosocial recalibration rather than a linear diagnosis-to-cure ...

A long-term metastatic ovarian cancer survivor explains how a trifecta of hope, purpose and grace has shaped her life through years of treatment.

A protocolized maintenance de-escalation permitted daratumumab cessation after ≥2 years plus ≥12 months sustained MRD negativity, with most patients not restarting at data cutoff. Generalizability is ...

Because Yank was treated as a pediatric patient, many of the other patients on his hospital floor were younger than 10. He ...

Metastatic breast cancer remains underfunded relative to incidence and lethality, and “survivor” messaging can marginalize ...

Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery. For some people with breast cancer, mastectomy ...

After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health ...

Lyrfigtu (lirafugratinib), a once-daily pill, is for previously treated cholangiocarcinoma with an FGFR2 fusion or ...

FDA expanded pirtobrutinib into frontline CLL/SLL for patients without del(17p), establishing a noncovalent BTK inhibitor option earlier in the treatment sequence. BRUIN CLL-313 demonstrated ...